Researchers sought to determine the effects of providing early interdisciplinary care on overall survival, progression-free survival, and adverse events in previously untreated patients with esophagogastric cancer.
Population-based analysis identified trends in incidence and disease-free survival for patients with advanced-stage carcinoma across 3 age groups.
Find the latest cancer treatment regimens for esophageal and esophagogastric junction cancers, including drugs such as ECF, cisplatin, and 5-FU.
Genomic copy number instability predicted the risk of disease progression among patients with Barrett esophagus years beforehand.
Prospective study shows increased risk for esophageal, gastric adenocarcinoma in two large cohorts.
Findings from a recent study support pretreatment screening for heart disease in patients with newly diagnosed, locoregional esophageal cancer.
In this study, skeletal muscle mass, as well as subcutaneous and visceral adiposity, were measured using CT imaging performed at baseline at the level of the L3 vertebrae.
In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.
In this study, patients were randomly assigned to receive standard-dose RT or standard-dose RT plus an integrated RT boost to the primary tumor.
Researchers present study findings that demonstrate the association between low-dose aspirin and risk for gastric or esophageal cancer at ESMO Congress 2019.
